According to the Zhitong Finance App, Peger Biopharmaceutical-B (02565.HK) announced interim results for the six months ended June 30, 2025. The group achieved other net losses of RMB 11.27 million (same unit), R&D expenses of RMB 110 million, and loss of 0.55 yuan per share.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.